News

Back

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

April 26th 2023

BSCB Dev

Mataró, Barcelona, Spain, April 25, 2023 - Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces 24-week interim results from NEXUS. This open label registration-enabling clinical trial is assessing the safety and efficacy of lead candidate leriglitazone, a novel, brain-penetrant and selective PPAR gamma agonist, to treat pediatric patients with cerebral adrenoleukodystrophy (cALD) - a phenotype of X-linked adrenoleukodystrophy (X-ALD). The results will be presented at the American Academy of Neurology 2023 Annual Meeting1

Read Pdf